More recently, Allen et al. investigated the efficacy of the anti-PDL-1 and anti-VEGFR2 antibody combination in mice bearing pancreatic neuroendocrine tumor, mammary carcinoma or glioblastoma [48]. This evidence concerns the gene CD274 and breast carcinoma.